A new study from researchers in Japan indicates that obstructive sleep apnea is independently associated with visceral (abdominal) fat accumulation only in men, perhaps explaining gender differences in the impact of OSA on cardiovascular disease and mortality.
Children who are exposed to secondhand smoke in early childhood are more likely to grow up to physically aggressive and antisocial, regardless of whether they were exposed during pregnancy or their parents have a history of being antisocial, according to Linda Pagani and Caroline Fitzpatrick of the University of Montreal...
Today the George Washington University School of Public Health and Health Services announced the launch of the Avance Center for the Advancement of Immigrant/Refugee Health, a collaboration between SPHHS, the Maryland Multicultural Youth Centers, the Rivera Group, and other community partners.
Living near a major roadway during the prenatal period is associated with an increased risk of respiratory infection developing in children by the age of 3, according to a new study from researchers in Boston.
Both fine-particle air pollution and noise pollution may increase a person's risk of developing cardiovascular disease, according to German researchers who have conducted a large population study, in which both factors were considered simultaneously.
Innovative and potentially game-changing clinical trials to develop new drug regimens to prevent and treat tuberculosis, the second leading global infectious disease killer, are in jeopardy due to federal "sequestration" funding cuts.
Use of the newer, more expensive intensity-modulated radiotherapy (IMRT) and use of the older conformal radiotherapy (CRT) after surgical removal of all or part of the prostate gland were associated with similar morbidity and cancer control outcomes, according to a study published Online First by JAMA Internal Medicine, a JAMA...
Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.